Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals - Discussion

Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals - Discussion

Bibliographic Details
Main Authors:	Davidson, M, Wood, D, Paoletti, R, Hobbs, R, Shepherd, J, Brown, W, Hunninghake, D, McKenney, J
Format:	Journal article
Published:	2003

Similar Items

Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin - Discussion
by: Stein, E, et al.
Published: (2003)

A comparative study of atorvastatin and rosuvastatin on lipid lowering efficacy in hyperlipidemic patients
by: Samia Haque Tonu, et al.
Published: (2018-03-01)

Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome
by: Abdulbari Bener, et al.
Published: (2014-07-01)

COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
by: Safina Shabbir, et al.
Published: (2020-12-01)

COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
by: Safina Shabbir, et al.
Published: (2020-12-01)

A comparison of the effectiveness of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels (according to the PROFILE-I registry)
by: Oleg V Gaisenok
Published: (2017-12-01)

LIPID-LOWERING EFFICACY OF 20 MG SIMVASTATIN VERSUS 5 MG ROSUVASTATIN IN PATIENTS OF TYPE 2 DIABETES
by: Hafiz Muhammad Yasir Rehman, et al.
Published: (2020-08-01)

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
by: Berne Christian, et al.
Published: (2005-06-01)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
by: Masadeh Majed, et al.
Published: (2012-05-01)

LIPID-LOWERING EFFICACY OF ROSUVASTATIN COMPARED WITH OTHER STATINS
by: A. N. Meshkov
Published: (2015-12-01)

LIPID-LOWERING EFFICACY OF ROSUVASTATIN COMPARED WITH OTHER STATINS
by: A. N. Meshkov
Published: (2015-12-01)

Rosuvastatin is Superior Compared to Simvastatin and Atorvastatin to Induce Endothelial Progenitor Cells Migration
by: Yudi Her Oktaviono, et al.
Published: (2019-05-01)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
by: Foody JM, et al.
Published: (2013-11-01)

Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo
by: Yinhui Liu, et al.
Published: (2018-03-01)

Lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction
by: N. A. Dzhaiani, et al.
Published: (2008-12-01)

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
by: Andrey Sivkov, et al.
Published: (2021-11-01)

EXPLORING LIPID LOWERING ACTIVITY OF CASSIA FISTULA AND SIMVASTATIN, IN HYPERLIPIDEMIC MICE
by: Usman Nawaz, et al.
Published: (2019-06-01)

Clinical, lipid-lowering, and pleiotropic effectiveness of rosuvastatin: a review of the GALAXY programme results
by: A. N. Britov, et al.
Published: (2011-02-01)

Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering.
by: Gounari, P, et al.
Published: (2010)

Mini meta-analysis of anticholinesterase actions of atorvastatin, simvastatin and rosuvastatin, and in silico identification of their protein targets in Mus musculus
by: Fouad Kasim Mohammad, et al.
Published: (2025-06-01)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
by: Gandhi SK, et al.
Published: (2012-01-01)

Simvastatin-induced nocturnal leg pain disappears with pravastatin substitution
by: Stojaković Nataša, et al.
Published: (2013-01-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model
by: Kaya Hacer Kayhan, et al.
Published: (2024-03-01)

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
by: Betteridge, D, et al.
Published: (1992)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
by: William Insull Jr, et al.
Published: (2010-11-01)

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
by: Tonkin, A, et al.
Published: (2000)

Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.
by: Gerd Hörl, et al.
Published: (2016-01-01)

Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
by: Anna Lis, et al.
Published: (2023-08-01)

Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin
by: M. I. Churilin, et al.
Published: (2020-03-01)

EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
by: A. Catapano, et al.
Published: (2013-08-01)

THE EFFECTS OF SIMVASTATIN, ROSUVASTATIN, AND FENOFIBRATE ON THE BODY WEIGHT AND LIPID PROFILES OF FEMALE RATS TREATED WITH ORAL CONTRACEPTIVES AND A HIGH-FAT DIET
by: Dwi Anggara Putri, et al.
Published: (2022-09-01)

Atorvastatin and simvastatin in clinical management of high-risk patients
by: S. A. Shalnova, et al.
Published: (2009-02-01)

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.
by: Reid, I, et al.
Published: (2001)

Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
by: David G Menter, et al.
Published: (2011-01-01)

Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study
by: Toivo Laks, et al.
Published: (2008-12-01)

Lipid-lowering and kidney
by: Sang-Hak Lee
Published: (2023-07-01)

Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.
by: Sarah A Stuart, et al.
Published: (2013-01-01)